{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:14:02Z","timestamp":1787328842894,"version":"build-2736575974"},"reference-count":22,"publisher":"Pharmaceutical Society of Japan","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,1,11]]},"DOI":"10.1248\/bpb.b24-00743","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T17:12:54Z","timestamp":1736529174000},"page":"6-10","source":"Crossref","is-referenced-by-count":3,"title":["Preventive and Therapeutic Effects of Intracerebroventricular Administration of Maresin-1 on Lipopolysaccharide-Induced Depression-Like Behaviors in Mice"],"prefix":"10.1248","volume":"48","author":[{"given":"Satoshi","family":"Deyama","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Ishikawa 920\u20131192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Kaneda","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Ishikawa 920\u20131192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masabumi","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). <i>J. Clin. Psychiatry<\/i>, <b>76<\/b>, 155\u2013162 (2015).","DOI":"10.4088\/JCP.14m09298"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. <i>Am. J. Psychiatry<\/i>, <b>163<\/b>, 28\u201340 (2006).","DOI":"10.1176\/appi.ajp.163.1.28"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanct\u00f4t KL. A meta-analysis of cytokines in major depression. <i>Biol. Psychiatry<\/i>, <b>67<\/b>, 446\u2013457 (2010).","DOI":"10.1016\/j.biopsych.2009.09.033"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein HC, Steiner J, Connor TJ, Harkin A, Versnel MA, Drexhage HA. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. <i>J. Leukoc. Biol.<\/i>, <b>92<\/b>, 959\u2013975 (2012).","DOI":"10.1189\/jlb.0212100"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. <i>Nature<\/i>, <b>510<\/b>, 92\u2013101 (2014).","DOI":"10.1038\/nature13479"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Serhan CN, Chiang N. Resolution phase lipid mediators of inflammation: agonists of resolution. <i>Curr. Opin. Pharmacol.<\/i>, <b>13<\/b>, 632\u2013640 (2013).","DOI":"10.1016\/j.coph.2013.05.012"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Deyama S, Ishikawa Y, Yoshikawa K, Shimoda K, Ide S, Satoh M, Minami M. Resolvin D1 and D2 reverse lipopolysaccharide-induced depression-like behaviors through the mTORC1 signaling pathway. <i>Int. J. Neuropsychopharmacol.<\/i>, <b>20<\/b>, 575\u2013584 (2017).","DOI":"10.1093\/ijnp\/pyx023"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ishikawa Y, Deyama S, Simoda K, Yoshikawa K, Ide S, Satoh M, Minami M. Rapid and sustained antidepressant effects of resolvin D1 and D2 in a chronic unpredictable stress model. <i>Behav. Brain Res.<\/i>, <b>332<\/b>, 233\u2013236 (2017).","DOI":"10.1016\/j.bbr.2017.06.010"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Deyama S, Shimoda K, Suzuki H, Ishikawa Y, Ishimura K, Fukuda H, Hitora-Imamura N, Ide S, Satoh M, Kaneda K, Shuto S, Minami M. Resolvin E1\/E2 ameliorate lipopolysaccharide-induced depression-like behaviors <i>via<\/i> ChemR23. <i>Psychopharmacology (Berl.)<\/i>, <b>235<\/b>, 329\u2013336 (2018).","DOI":"10.1007\/s00213-017-4774-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Aoki S, Deyama S, Sugie R, Ishimura K, Fukuda H, Shuto S, Minami M, Kaneda K. The antidepressant effect of resolvin E1 in repeated prednisolone-induced depression model mice. <i>Behav. Brain Res.<\/i>, <b>418<\/b>, 113676 (2022).","DOI":"10.1016\/j.bbr.2021.113676"},{"key":"11","unstructured":"11) Franklin KBJ, Paxinos G. <i>The mouse brain in stereotaxic coordinates.<\/i> Third ed., Elsevier, Burlington, MA (2007)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Deyama S, Kondo M, Shimada S, Kaneda K. IGF-1 release in the medial prefrontal cortex mediates the rapid and sustained antidepressant-like actions of ketamine. <i>Transl. Psychiatry<\/i>, <b>12<\/b>, 178 (2022).","DOI":"10.1038\/s41398-022-01943-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Deyama S, Aoki S, Sugie R, Fukuda H, Shuto S, Minami M, Kaneda K. Intranasal administration of resolvin E1 produces antidepressant-like effects <i>via<\/i> BDNF\/VEGF-mTORC1 signaling in the medial prefrontal cortex. <i>Neurotherapeutics<\/i>, <b>20<\/b>, 484\u2013501 (2023).","DOI":"10.1007\/s13311-022-01337-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Dantzer R, O\u2019Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. <i>Nat. Rev. Neurosci.<\/i>, <b>9<\/b>, 46\u201356 (2008).","DOI":"10.1038\/nrn2297"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Shi L, Xia Z, Guo J, Wang L, Peng Z, Qiu D, Zhou Y, Zhou D, Kuang L, Qiu T. Maresin-1 improves LPS-induced depressive-like behavior by inhibiting hippocampal microglial activation. <i>J. Affect. Disord.<\/i>, <b>328<\/b>, 261\u2013272 (2023).","DOI":"10.1016\/j.jad.2023.02.016"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Wohleb ES, Franklin T, Iwata M, Duman RS. Integrating neuroimmune systems in the neurobiology of depression. <i>Nat. Rev. Neurosci.<\/i>, <b>17<\/b>, 497\u2013511 (2016).","DOI":"10.1038\/nrn.2016.69"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Xian W, Wu Y, Xiong W, Li L, Li T, Pan S, Song L, Hu L, Pei L, Yao S, Shang Y. The pro-resolving lipid mediator maresin 1 protects against cerebral ischemia\/reperfusion injury by attenuating the pro-inflammatory response. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>472<\/b>, 175\u2013181 (2016).","DOI":"10.1016\/j.bbrc.2016.02.090"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Qiu T, Li X, Chen W, He J, Shi L, Zhou C, Zheng A, Lei Z, Tang C, Yu Q, Du L, Guo J. Prospective study on maresin-1 and cytokine levels in medication-na\u00efve adolescents with first-episode major depressive disorder. <i>Front. Psychiatry<\/i>, <b>14<\/b>, 1132791 (2023).","DOI":"10.3389\/fpsyt.2023.1132791"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. <i>Arch. Gen. Psychiatry<\/i>, <b>63<\/b>, 856\u2013864 (2006).","DOI":"10.1001\/archpsyc.63.8.856"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Duman RS, Deyama S, Foga\u00e7a MV. Role of BDNF in the pathophysiology and treatment of depression: activity-dependent effects distinguish rapid-acting antidepressants. <i>Eur. J. Neurosci.<\/i>, <b>53<\/b>, 126\u2013139 (2021).","DOI":"10.1111\/ejn.14630"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Ma M, Ren Q, Yang C, Zhang JC, Yao W, Dong C, Ohgi Y, Futamura T, Hashimoto K. Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation. <i>Psychopharmacology<\/i> (Berl.), <b>234<\/b>, 525\u2013533 (2017).","DOI":"10.1007\/s00213-016-4483-7"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Wei J, Su W, Zhao Y, Wei Z, Hua Y, Xue P, Zhu X, Chen Y, Chen G. Maresin 1 promotes nerve regeneration and alleviates neuropathic pain after nerve injury. <i>J. Neuroinflammation<\/i>, <b>19<\/b>, 32 (2022).","DOI":"10.1186\/s12974-022-02405-1"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/1\/48_b24-00743\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T22:28:15Z","timestamp":1736548095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/1\/48_b24-00743\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b24-00743","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]},"article-number":"b24-00743"}}